Insulin Degludec Patent Expiration
Insulin Degludec is used for lowering blood pressure and treating heart failure and kidney problems. It was first introduced by Novo Nordisk Inc
Insulin Degludec Patents
Given below is the list of patents protecting Insulin Degludec, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tresiba | US9132239 | Dial-down mechanism for wind-up pen | Feb 01, 2032 | Novo |
| Tresiba | US7615532 | Insulin derivatives | Jun 28, 2029 | Novo |
| Tresiba | US9457154 | Injection device with an end of dose feedback mechanism | Sep 27, 2027 | Novo |
| Tresiba | US9687611 | Injection device with torsion spring and rotatable display | Feb 27, 2027 | Novo |
| Tresiba | US7686786 | Dial-down mechanism for wind-up pen | Aug 03, 2026 | Novo |
| Tresiba | USRE46363 | Dial-down mechanism for wind-up pen | Aug 03, 2026 | Novo |
| Tresiba | US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism | Jul 17, 2026 | Novo |
| Tresiba | US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Tresiba | US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Tresiba | US10357616 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Tresiba | US10376652 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Tresiba | US9108002 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Tresiba | US9616180 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Tresiba | US9861757 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Tresiba | US8684969 | Injection device with torsion spring and rotatable display | Oct 20, 2025 | Novo |
| Tresiba | US7762994 | Needle mounting system and a method for mounting a needle assembly |
May 23, 2024
(Expired) | Novo |
| Tresiba | US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun 30, 2023
(Expired) | Novo |
| Tresiba | US6899699 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Tresiba | US8672898 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Tresiba | US9486588 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Degludec's patents.
Latest Legal Activities on Insulin Degludec's Patents
Given below is the list recent legal activities going on the following patents of Insulin Degludec.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2021 | US7615532 |
| Patent Term Extension Certificate Critical | 11 Sep, 2018 | US7615532 |
| Notice of Final Determination -Eligible | 14 Mar, 2018 | US7615532 |
| FDA Final Eligibility Letter Critical | 20 Sep, 2017 | US7615532 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED Critical | 18 Apr, 2017 | US7615532 |
| Terminal Disclaimer Filed Critical | 14 Apr, 2017 | US7615532 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 13 Apr, 2017 | US7615532 |
| Terminal Disclaimer Filed Critical | 10 Apr, 2017 | US7615532 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED Critical | 10 Apr, 2017 | US7615532 |
| transaction for FDA Determination of Regulatory Review Period | 07 Dec, 2016 | US7615532 |
Insulin Degludec's Family Patents
